Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026

Quince Therapeutics, Inc.

Reverse stock split ratio set at 1-for-20, approved by board after stockholder authorization.
Certificate of Amendment filed with Delaware; effective 11:59 pm ET June 29.
Shares trade split-adjusted on Nasdaq starting June 30; new CUSIP 22053A305.
Outstanding shares reduce from ~19.56M to ~0.98M; fractional shares rounded up.
All options and warrants proportionally adjusted; Equiniti Trust acts as exchange agent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.